# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...
Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from $2.5...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0....
BIOLASE, Inc. shares rise 31% after better-than-expected FY23 EPS results, strong revenue growth expected in 2024 due to increa...
U.S. stocks traded slightly lower this morning. Following the market opening Friday, the Dow traded down 0.06% to 39,758.88 whi...